Haemophilia A
81
8
9
64
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
18 trials with published results (22%)
Research Maturity
64 completed trials (79% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.7%
3 terminated out of 81 trials
95.5%
+9.0% vs benchmark
28%
23 trials in Phase 3/4
28%
18 of 64 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 64 completed trials
Clinical Trials (81)
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI
A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge
Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®
An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct
Register of Patients With haEmophilia A tReated With Afstyla®
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B